Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$21.37M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
299.06%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$8.909M
Q3 2024
Cash
Q3 2024
P/E
-2.284
Nov 29, 2024 EST
Free Cash Flow
-$17.51M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2023 2022 2021 2020 2019
Revenue $55.18K $140.1K $165.0K $28.88K $40.00K
YoY Change -60.62% -15.08% 471.29% -27.8% 100.0%

Expenses

Cost Of Revenues

No data

Gross Profit

No data

Gross Profit Margin

No data

Gross Profit

Concept 2023 2022 2021 2020 2019
Revenue $55.18K $140.1K $165.0K $28.88K $40.00K
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

No data

R&D To Gross Profit Ratio

No data

DDA To Gross Profit Ratio

No data

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2023 2022 2021 2020 2019
Selling, General & Admin $10.88M $9.540M $6.827M $1.250M $560.0K
YoY Change 14.09% 39.74% 446.16% 123.21% 154.55%
% of Gross Profit
Research & Development $11.38M $8.377M $7.164M $2.259M $1.590M
YoY Change 35.83% 16.93% 217.11% 42.09% 91.57%
% of Gross Profit
Depreciation & Amortization $83.58K $64.17K $15.48K $9.592K $0.00
YoY Change 30.25% 314.41% 61.43%
% of Gross Profit
Operating Expenses $22.31M $17.92M $13.99M $3.508M $2.140M
YoY Change 24.51% 28.06% 298.8% 63.94% 103.81%
Operating Profit -$22.25M -$17.78M -$13.83M -$3.479M
YoY Change 25.18% 28.58% 297.37%

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

No data

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019
Interest Expense $64.88K $279.3K -$60.42K -$90.00K -$90.00K
YoY Change -76.77% -562.25% -32.87% 0.0% 28.57%
% of Operating Profit
Other Income/Expense, Net
YoY Change

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2023 2022 2021 2020 2019
Pretax Income -$22.19M -$17.50M -$13.89M -$3.572M -$2.190M
YoY Change 26.81% 26.0% 288.73% 63.12% 99.09%
Income Tax $79.28K $92.98K $4.008K $5.386K $10.00K
% Of Pretax Income
Net Earnings -$22.27M -$17.59M -$13.89M -$3.578M -$2.190M
YoY Change 26.59% 26.64% 288.26% 63.36% 97.3%
Net Earnings / Revenue -40354.33% -12555.13% -8418.86% -12387.67% -5475.0%
Basic Earnings Per Share -$1.71 -$1.48 -$1.37 -$1.33
Diluted Earnings Per Share -$1.71 -$1.48 -$1.37 -$1.33 -$193.3K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

No data

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

No data

Assets & Liabilities

Concept 2023 2022 2021 2020 2019
Cash & Short-Term Investments $16.79M $20.14M $36.88M $7.490M $300.0K
YoY Change -16.6% -45.4% 392.4% 2396.67%
Cash & Equivalents $6.767M $4.401M $33.62M $7.490M $300.0K
Short-Term Investments $5.000M $17.23M $33.62M
Other Short-Term Assets $741.6K $761.4K $645.9K $1.430M $80.00K
YoY Change -2.6% 17.88% -54.83% 1687.5%
Inventory
Prepaid Expenses
Receivables $0.00 $10.00K $10.00K
Other Receivables $195.5K $60.00K $30.00K
Total Short-Term Assets $17.78M $21.09M $37.72M $8.990M $430.0K
YoY Change -15.71% -44.09% 319.6% 1990.7%
Property, Plant & Equipment $778.6K $1.018M $1.210M $550.0K $220.0K
YoY Change -23.54% -15.82% 119.93% 150.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $1.941M
YoY Change -100.0%
Other Assets $51.91K $48.32K $53.39K $60.00K $10.00K
YoY Change 7.43% -9.5% -11.02% 500.0%
Total Long-Term Assets $830.5K $3.008M $1.263M $610.0K $230.0K
YoY Change -72.39% 138.16% 107.05% 165.22%
Total Assets $18.61M $24.10M $38.99M $9.600M $660.0K
YoY Change
Accounts Payable $1.319M $1.626M $560.5K $960.0K $150.0K
YoY Change -18.89% 190.13% -41.62% 540.0%
Accrued Expenses $1.973M $1.972M $1.366M $800.0K $310.0K
YoY Change 0.05% 44.31% 70.79% 158.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $118.8K $108.1K $103.8K $20.00K $0.00
YoY Change 9.86% 4.15% 419.15%
Total Short-Term Liabilities $4.950M $4.125M $2.553M $2.110M $880.0K
YoY Change 19.99% 61.61% 20.97% 139.77%
Long-Term Debt $449.1K $495.3K $590.5K $720.0K $0.00
YoY Change -9.33% -16.12% -17.99%
Other Long-Term Liabilities $632.1K $599.4K $1.025M $570.0K $230.0K
YoY Change 5.46% -41.5% 79.74% 147.83%
Total Long-Term Liabilities $1.081M $1.095M $1.615M $1.290M $230.0K
YoY Change -1.23% -32.22% 25.19% 460.87%
Total Liabilities $6.031M $5.220M $4.168M $3.400M $1.110M
YoY Change 15.54% 25.25% 22.57% 206.31%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2023 2022 2021 2020 2019
Basic Shares Outstanding 13.01M 11.88M 10.17M 2.681M
Diluted Shares Outstanding 13.01M 11.88M 10.17M 2.681M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $48.806 Million

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. The company is headquartered in Bethesda, Maryland and currently employs 29 full-time employees. The company went IPO on 2021-03-18. The firm is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of GCase function, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.

Industry: Pharmaceutical Preparations Peers: Aligos Therapeutics, Inc. Applied Molecular Transport Inc. Protara Therapeutics, Inc. Athenex, Inc. BeyondSpring Inc. CASI Pharmaceuticals, Inc (DE) PhaseBio Pharmaceuticals Inc Eledon Pharmaceuticals, Inc. Molecular Templates, Inc.